Recent advancement of nanomedicine-based targeted delivery for cervical cancer treatment

被引:0
作者
Rakhi Yadav
Priyanku Pradip Das
Sunil Sharma
Sounok Sengupta
Deepak Kumar
Ram Sagar
机构
[1] Jawaharlal Nehru University,Glycochemistry Laboratory, School of Physical Sciences
[2] Shoolini University,Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences
[3] Shoolini University,Department of Pharmacology, School of Pharmaceutical Sciences
来源
Medical Oncology | / 40卷
关键词
Nanomedicine; Oncoproteins; Pathophysiology; Angiogenesis; Cervical cancer; Immunotherapy; Tumor suppressor genes;
D O I
暂无
中图分类号
学科分类号
摘要
Cervical cancer is a huge worldwide health burden, impacting women in impoverished nations in particular. Traditional therapeutic approaches, such as surgery, radiation therapy, and chemotherapy, frequently result in systemic toxicity and ineffectiveness. Nanomedicine has emerged as a viable strategy for targeted delivery of therapeutic drugs to cancer cells while decreasing off-target effects and increasing treatment success in recent years. Nanomedicine for cervical cancer introduces several novel aspects that distinguish it from previous treatment options such as tailored delivery system, precision targeting, combination therapies, real-time monitoring and diverse nanocarriers to overcome the limitations of one another. This abstract presents recent advances in nanomedicine-based tailored delivery systems for the treatment of cervical cancer. Liposomes, polymeric nanoparticles, dendrimers, and carbon nanotubes have all been intensively studied for their ability to transport chemotherapeutic medicines, nucleic acids, and imaging agents to cervical cancer cells. Because of the way these nanocarriers are designed, they may cross biological barriers and preferentially aggregate at the tumor site, boosting medicine concentration and lowering negative effects on healthy tissues. Surface modification of nanocarriers with targeting ligands like antibodies, peptides, or aptamers improves specificity for cancer cells by identifying overexpressed receptors or antigens on the tumor surface. Furthermore, nanomedicine-based techniques have made it possible to co-deliver numerous therapeutic drugs, allowing for synergistic effects and overcoming drug resistance. In preclinical and clinical investigations, combination treatments comprising chemotherapeutic medicines, gene therapy, immunotherapy, and photodynamic therapy have showed encouraging results, opening up new avenues for individualized and multimodal treatment regimens. Furthermore, the inclusion of contrast agents and imaging probes into nanocarrier systems has enabled real-time monitoring and imaging of treatment response. This enables the assessment of therapy efficacy, the early diagnosis of recurrence, and the optimization of treatment regimens.
引用
收藏
相关论文
共 726 条
[1]  
Kumar A(2023)Recent advancements in Triazole-b ased click chemistry in cancer drug discovery and development SynOpen 7 186-208
[2]  
Yadav AK(2023)Phenothiazines as anti-cancer agents: SAR overview and synthetic strategies Eur J Med Chem 254 10-41
[3]  
Mishra V(2022)Advances in lung cancer treatment using nanomedicines ACS Omega 8 320-760
[4]  
Kumar D(2023)Metal-based nanomaterials and nanocomposites as promising frontier in cancer chemotherapy Medcomm 4 751-104
[5]  
Kumar A(2022)Nano-based theranostic platforms for breast cancer: a review of latest advancements Bioengineering 9 103-1018
[6]  
Vigato C(2023)Recent advancements in the targeted delivery of etoposide nanomedicine for cancer therapy: a comprehensive review Eur J Med Chem 259 1001-4
[7]  
Boschi D(2007)84 Nat nanotech 2007 R Langer Nanocarriers as an emerging platform for cancer therapy.pdf Nat Nanotechnol 2 3-232
[8]  
Lolli ML(2009)Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium Int J Gynaecol Obstet 105 223-163
[9]  
Kumar D(2015)Polymeric nanoparticles for targeted treatment in oncology: current insights Int J Nanomed 10 150-647
[10]  
Sharma A(2020)Cervical cancer: a meta-analysis, therapy and future of nanomedicine Ecancermedicalscience 14 641-20